MGWM
KYMR icon

Marks Group Wealth Management’s Kymera Therapeutics KYMR Stock Holding History

Marks Group Wealth Management’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$507K Buy
4,422
+419
+10% +$36K 0.04% 264
2026
Q1 		$333K Buy
+4,003
New +$317K 0.03% 284

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Marks Group Wealth Management's KYMR Position: Q2 2026 in Review

Marks Group Wealth Management increased its Kymera Therapeutics (KYMR) stake by 10% in Q2 2026, buying an estimated $36K and bringing the position to 4,422 shares worth $507K. The position accounts for 0.04% of the portfolio, ranked #264.

Marks Group Wealth Management first reported a position in KYMR in Q1 2026 and has held it in 2 quarters since. 275 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • Marks Group Wealth Management held 4,422 shares of Kymera Therapeutics worth $507K as of Q2 2026.
  • Marks Group Wealth Management bought 419 Kymera Therapeutics shares in Q2 2026, an estimated $36K.
  • Kymera Therapeutics made up 0.04% of Marks Group Wealth Management's portfolio in Q2 2026, its #264 holding.
  • Marks Group Wealth Management first reported a position in Kymera Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 275 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on Marks Group Wealth Management's 13F filing for Q2 2026, filed 28 Jul 2026.